Brief Communication
Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma
M. Pereira Barbosaa, A. Bugalho de Almeidab, C. Pereirac,
, C.-W. Chend, P. Georgioue, G. Peacheye, on behalf of eXpeRience study group
Corresponding author
a Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Norte, Lisbon, Portugal
b Clínica Universitária de Pneumologia, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
c Novartis Farma – Produtos Farmaceuticos S.A., Avenida Professor Doutor Cavaco Silva, n.° 10E, Taguspark, 2740-255 Porto Salvo, Portugal
d Novartis Pharmaceuticals Corporation, One Health Plaza East Hanover, NJ 07936-1080, USA
e Novartis Pharmaceuticals UK Limited, Wimblehurst Road Horsham, West Sussex RH12 5AB, UK
Read
1557
Timeswas read the article
772
Total PDF
785
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 9 | 8 | 17 |
| 2025 5 | 63 | 51 | 114 |
| 2025 4 | 55 | 37 | 92 |
| 2025 3 | 43 | 31 | 74 |
| 2025 2 | 44 | 30 | 74 |
| 2025 1 | 26 | 34 | 60 |
| 2024 12 | 23 | 31 | 54 |
| 2024 11 | 31 | 42 | 73 |
| 2024 10 | 24 | 29 | 53 |
| 2024 9 | 27 | 24 | 51 |
| 2024 8 | 39 | 51 | 90 |
| 2024 7 | 28 | 30 | 58 |
| 2024 6 | 30 | 20 | 50 |
| 2024 5 | 33 | 35 | 68 |
| 2024 4 | 28 | 24 | 52 |
| 2024 3 | 34 | 23 | 57 |
| 2024 2 | 27 | 30 | 57 |
| 2024 1 | 18 | 18 | 36 |
| 2023 12 | 17 | 28 | 45 |
| 2023 11 | 21 | 25 | 46 |
| 2023 10 | 17 | 44 | 61 |
| 2023 9 | 20 | 28 | 48 |
| 2023 8 | 18 | 19 | 37 |
| 2023 7 | 22 | 26 | 48 |
| 2023 6 | 15 | 13 | 28 |
| 2023 5 | 43 | 29 | 72 |
| 2023 4 | 30 | 12 | 42 |
Show all
